Nancy Lin presents the latest findings from the HER2CLIMB trial, reporting on the intracranial efficacy of tucatinib given alongside trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases (5:12).
29-05-2020 | ASCO 2020 | Conference coverage | Video